Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dihydronicotinic acid riboside
- Development stage
- Preclinical
- Lead developer
- ChromaDex
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal
01
Overview
Dihydronicotinic acid riboside (NARH) is a small molecule research compound that serves as a potent precursor to nicotinamide adenine dinucleotide (NAD+). As the reduced form of nicotinic acid riboside (NAR), NARH has been shown to effectively increase intracellular NAD+ levels, particularly in hepatic cells. Research conducted by the Nestlé Institute of Health Sciences and ChromaDex indicates that NARH may work synergistically with other precursors like nicotinamide riboside (NR) to enhance NAD+ metabolism. It is being explored for its potential therapeutic benefits in healthy aging and metabolic conditions associated with NAD+ depletion.
- Other names
- reduced nicotinic acid riboside1-(beta-D-ribofuranosyl)-1,4-dihydropyridine-3-carboxylic acid
02
Targets
SIRT5 (NAD-dependent protein deacylase sirtuin-5, mitochondrial)NAD+ metabolism
Beyond the preview
Go deeper on dihydronicotinic acid riboside.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dihydronicotinic acid riboside.